Background and aims: Type 2 diabetes (T2D), low-density lipoprotein-cholesterol (LDL-c),
INTRODUCTION
In recent years many genome wide association studies (GWAS) have been conducted for established and non-established risk factors for CAD (Supplementary Table 1) 1-33 with the aim to discovering genetic determinants of risk factors. For each of the 60 a priori-selected risk factors, Supplementary Table 1 lists the studies and their characteristics used in this analysis. Even if tested, in most cases the relative contribution of risk factors to CAD has not been comprehensively investigated, since each study typically tests for the association of only one or two traits with CAD at any one time.
Our goal was to comprehensively evaluate the associations of established and emerging risk factors with CAD using genetic variants identified from GWAS. The rationale is that this could identify risk factors for follow up studies, for example in much larger and more comprehensive Mendelian randomization (MR) studies, and/or provide support for ongoing clinical trials targeting selected biomarkers. Furthermore this may increase our understanding of the aetiological and genetic landscape of CAD.
METHODS

Trait selection
To identify GWAS of established and non-established risk factors for CAD we queried the NHGRI GWAS Catalogue (available at: http://www.ebi.ac.uk/gwas/) in May 2015. GWAS with summary level data on SNP, effect size, standard error of effect size, risk allele and risk allele frequency publicly available in the GWAS catalog or in the original paper were included in the analysis.
We considered T2D, LDL-c, BMI, blood pressure and smoking to be established risk factors for CAD. The non-established risk factors were selected from the GWAS Catalogue by reviewing the traits in the GWAS catalog, and select potential traits of interest. Each trait in the GWAS Catalogue which has been linked to CAD based on its pathophysiology in the 40 , homoarginine levels 41 ,serum uric acid levels 42 , serum dimethylarginine levels (symmetric) 43 , serum dimethylarginine levels (assymetric/symmetric rate) 44 , fat body mass(FBM) 45 , and chronic kidney disease(CKD) 46 ).
SNPs selection for association
For all analyses, we selected SNPs that reached a significance level of at least p<5E-08 in the original GWAS of European individuals.
The goal was to test the association between the SNPs associated with risk factors and risk of CAD. For each trait we only selected independent SNPs (not in linkage disequilibrium (LD) with other SNPs for the same trait at r 2 cut-off<0.5). If two SNP were in LD this means that the alleles of both SNPs are inherited together more often than would be expected by chance.
When we encountered SNPs in LD, the variant with the most significant p-value for the trait of interest was included in the analysis for that trait.
Traits with a significant association with CAD after the first analysis were selected for a secondary analysis to investigate independence of association by removing SNPs with pleiotropic effects. To do this, we categorized traits into two groups; "upstream" and We limited our study to GWAS performed in Caucasians since the CARDIoGRAM validation dataset is of the same ethnicity.
RESULTS
Trait selection
We included 69 studies in which a total of 60 risk factors were described. Supplementary Table 1 provides an overview of the papers incorporated in the analysis, listing the unit of exposure per increased risk allele, the variance explained by the reported SNPs, the number of SNPs discovered and the sample size of the study.
SNPs selection for association.
The number of SNPs remaining after excluding duplicates and correcting for LD can be found in Table 1 . Height was the trait with most SNPs (173) whereas some traits only had one SNP (e.g. smoking cessation). With these SNPs we performed a genetic association analysis with CAD using the CARDIoGRAM data.
Association of risk factors with CAD using all independent SNPs
In our analysis 15 out of 60 risk factors (Table 1) p=3.13E-23.
As a negative control, we tested eye color as a risk factor: no association between eye color and CAD risk was found ORCAD=1.00, 95% CI: 0.99 -1.02 p=0.93. Table 2 provides the number of SNPs that remained after pleiotropic SNPs were excluded.
Association of risk factors with CAD using non-pleiotropic SNPs
We analyzed 15 risk factors in our secondary analysis ( Table 2 ) and found that six of the 15 traits had a significant association; the lowest p-value and highest effect size for CAD was for CAC ORCAD 1.91,95% CI: 1.68-2.16 p=3.13E-23. In contrast to the primary analysis, no significant association was identified for LP-PLA2, T2D, HDL-c, SBP, DBP, MAP, vWF and FVIII when SNPs were thinned out by pleiotropy (Figure 1) .
DISCUSSION
We conducted a comprehensive study to investigate the association of risk factors for their association with CAD using summary-level genetic data. Using all available SNPs, we found a significant association with CAD for the following traditional risk factors: LDL-C, HDL-C, SBP, DBP, BMI, T2D and TG. In addition, we found the following traits to associate with CAD: Height, CAC, Lp(a), LP-PLA2, plaque, factor VIII, von willebrand factor and mean arterial pressure. Of these emerging risk factors, when we removed potentially pleiotropic SNPs, associations with CAD persisted for Height, CAC, Lp(a), and plaque.
After removing potentially pleiotropic SNPs for FVIII and vWF, the association with CAD no longer persisted. Furthermore, the association between LP-PLA2 and CAD also diminished when limited to nominally non-pleiotropic SNPs, which is in keeping with a recent MR study 48 . This arises from an overlap in genetic variation between LP-PLA2 activity and lipid phenotypes in our data: 6 of 9 LP-PLA2 SNPs in our primary analysis where excluded in our secondary analysis because they were in LD with one of the lipid (LDL-C, HDL-C or TG)
phenotypes. An explanation for this phenomena might be that in the bloodstream, two-thirds of LP-PLA2 circulates primarily bound to LDL; the remaining third is distributed between HDL and VLDL 49 . Measures of LP-PLA2 might thus partially reflect the concentration of proatherogenic lipoproteins. Recent clinical trials with the LP-PLA2 inhibitor darapladib in coronary heart disease patients yield similar results to our analysis 50, 51 . In patients with stable CAD after optimal treatment for dyslipidemia, there was no added benefit of reducing LP-PLA2. Regarding vWF, other studies identified a weak association between vWF levels and CAD but it disappeared after adjusting for coexisting riskfactors 52, 53 For IMT and PAI-1, we do not find an association with CAD in our primary analysis. This is in contrast with other studies 3, 17 . This may be due to low variance of the exposure explained by the SNPs for IMT (1.10% Although HDL-C associated with CAD on initial analysis, when we limited the genetic instrument to only non-pleiotropic SNPs, this association diminished. This is in keeping with prior reports [56] [57] [58] [59] To take one example, in the paper by Voight et al., a Mendelian randomization analysis was conducted using a genetic risk score consisting of 14 common
SNPs that associated predominantly with HDL cholesterol and tested this score in up to 12,482 cases of myocardial infarction and 41,331 controls. They found that a 1 SD increase in HDL cholesterol due to genetic score was not associated with risk of myocardial infarction (OR 0.93, 95% CI 0.68-1.26, p=0.63) 58 .
Interestingly, in our analysis restricted to non-pleiotropic SNPs, the established causal risk factors SBP and DBP were no longer associated with CAD. This arose because restricting to non-pleiotropic SNPs resulted in the removal of the majority of SNPs with only 3 SNPs remaining for DBP and 1 SNP for SBP. SNPs were removed because they were also associated with MAP, PP, HTN. While the causal role of blood pressure in CAD is wellestablished, this suggests that our approach overly-penalized some traits that have a highly pleiotropic genetic architecture.
The association of CAC and plaque with CAD retained after removing pleiotropic SNPs and is worthy of further comment. Over the past few years there has been a move to use surrogate markers of CHD in clinical trials as a marker of "hard" clinical outcomes, but at a lower cost than conducting a full outcome-based clinical trial. Given that these downstream traits are proximal to the CAD phenotype, they are less likely to be confounded compared to a trait that is more distant (or upstream trait, such as a blood lipid profile). Our data therefore suggest that, given the relationship of these traits with risk of CAD, that they may represent a proxy for CAD, however further investigations are needed, for example relating SNPs such as LDL-C and SBP on plaque and CAC 60 to see whether they associate with these traits.
Our study has several strengths and weaknesses that merit discussion. To the best of our knowledge we are the first to report on the association between SNPs associated with multiple non-established risk factors and risk of CAD. We are, however restricted to published studies, which might have resulted in selection bias. Furthermore, the data was derived from the publications, and no source data quality assessment could be performed, we were dependent on the quality of the published papers. As an example, traits where the genetic landscape is not fully captured by current GWAS might bias our results. Therefore, at the moment we cannot rule out any association between these risk factors and CAD. Because summary level data were used for analyses, we were not able to perform age and gender corrections (however these would have been conducted in the original GWAS); we are therefore dependent on the corrections performed in the published papers. Finally, this study represents a rather broad but crude genetic analysis; more sophisticated analyses such as multivariate MR 61 and/or MR-Egger 62 would represent next steps to more comprehensively assessing and accounting for pleiotropy of genetic instruments and testing for independence of causal estimates across multiple risk factors.
In conclusion, our multiple trait genetic analysis of established and emerging risk factors for CAD provides further evidence that TG and Lp(a) should be prioritized as potential therapeutic targets for CAD prevention, and suggests that CAC and plaque could be potential surrogate markers for CAD. Text:
In secondary analysis we excluded SNPs that overlapped between traits or were in linkage disequilibrium across traits from analysis. As can be noted, there was a large overlap between the genetic variation for Systolic and Diastolic blood pressure. Six traits were significantly associated with CAD Text:
In secondary analysis we excluded SNPs that overlapped between traits or were in linkage disequilibrium across traits from analysis. Five traits are also associated with CAD in our secondary analysis. Odds ratios (grey bars) and 95% confidence intervals (black lines) are shown for both methods. Traits with an asterisk are associated with CAD in both the primary and secondary analysis.
